Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review.
cytomegalovirus
disease burden
emerging markets
epidemiology
solid organ transplantation
systematic review
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
17
04
2023
received:
21
02
2023
accepted:
06
05
2023
medline:
15
8
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) is a frequent infectious complication following solid organ transplantation (SOT). Considering significant differences in healthcare systems, a systematic review was conducted to describe the epidemiology, management, and burden of CMV post-SOT in selected countries outside of Europe and North America. MEDLINE, Embase, and Cochrane databases were searched for observational studies in SOT recipients across 15 countries in the regions of Asia, Pacific, and Latin America (search period: January 1, 2011 to September 17, 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatment patterns and guidelines, refractory and/or resistant CMV, patient-reported outcomes, and economic burden. Of 2708 studies identified, 49 were eligible (n = 43/49; 87.8% in adults; n = 34/49, 69.4% in kidney recipients). Across studies, selection of CMV preventive strategy was based on CMV serostatus. Overall, rates of CMV infection (within 1 year) and CMV disease post-SOT were respectively, 10.3%-63.2% (9 studies) and 0%-19.0% (17 studies). Recurrence occurred in 35.4%-41.0% cases (3 studies) and up to 5.3% recipients died of CMV-associated causes (11 studies). Conventional treatments for CMV infection/disease included ganciclovir (GCV) or valganciclovir. Up to 4.4% patients were resistant to treatment (3 studies); no studies reported on refractory CMV. Treatment-related adverse events with GCV included neutropenia (2%-29%), anemia (13%-48%), leukopenia (11%-37%), and thrombocytopenia (13%-24%). Data on economic burden were scarce. Outside of North America and Europe, rates of CMV infection/disease post-SOT are highly variable and CMV recurrence is frequent. CMV resistance and treatment-associated adverse events, including myelosuppression, highlight unmet needs with conventional therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Cytomegalovirus (CMV) is a frequent infectious complication following solid organ transplantation (SOT). Considering significant differences in healthcare systems, a systematic review was conducted to describe the epidemiology, management, and burden of CMV post-SOT in selected countries outside of Europe and North America.
METHODS
METHODS
MEDLINE, Embase, and Cochrane databases were searched for observational studies in SOT recipients across 15 countries in the regions of Asia, Pacific, and Latin America (search period: January 1, 2011 to September 17, 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatment patterns and guidelines, refractory and/or resistant CMV, patient-reported outcomes, and economic burden.
RESULTS
RESULTS
Of 2708 studies identified, 49 were eligible (n = 43/49; 87.8% in adults; n = 34/49, 69.4% in kidney recipients). Across studies, selection of CMV preventive strategy was based on CMV serostatus. Overall, rates of CMV infection (within 1 year) and CMV disease post-SOT were respectively, 10.3%-63.2% (9 studies) and 0%-19.0% (17 studies). Recurrence occurred in 35.4%-41.0% cases (3 studies) and up to 5.3% recipients died of CMV-associated causes (11 studies). Conventional treatments for CMV infection/disease included ganciclovir (GCV) or valganciclovir. Up to 4.4% patients were resistant to treatment (3 studies); no studies reported on refractory CMV. Treatment-related adverse events with GCV included neutropenia (2%-29%), anemia (13%-48%), leukopenia (11%-37%), and thrombocytopenia (13%-24%). Data on economic burden were scarce.
CONCLUSION
CONCLUSIONS
Outside of North America and Europe, rates of CMV infection/disease post-SOT are highly variable and CMV recurrence is frequent. CMV resistance and treatment-associated adverse events, including myelosuppression, highlight unmet needs with conventional therapy.
Substances chimiques
Ganciclovir
P9G3CKZ4P5
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14070Subventions
Organisme : Takeda Pharmaceuticals International AG-Singapore Branch
Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512. doi:10.1111/ctr.13512
Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70(7):515-523. doi:10.6061/clinics/2015(07)09
Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2016;64(1):87-91. doi:10.1093/cid/ciw668
Pérez-Sola MJ, Caston JJ, Solana R, Torre-Cisneros J. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin. 2008;26(1):38-47. doi:10.1157/13114394
Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014;58(6):785-803. doi:10.1093/cid/cit945
Kim MJ, You, JH, Yeh HR, Lee JA, Lee JH, Park YS. Cytomegalovirus infection in pediatric renal transplant recipients: a single center experience. Child Kidney Dis. 2017;21(2):75-80. doi:10.3339/jkspn.2017.21.2.75
Toussaint ND, Tan MB, Nicholls K, Walker RG, Cohney SJ. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Nephrology. 2011;16(1):113-137. doi:10.1111/j.1440-1797.2010.01379.x
Cristelli MP, Esmeraldo RM, Pinto C, et al. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients. Transpl Infect Dis. 2018;20(4):e12907. doi:10.1111/tid.12907
Reusing Jr JO, Feitosa EB, Agena F, et al. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease. Transpl Infect Dis. 2018;20(5):e12929. doi:10.1111/tid.12929
Cho SY, Lee DG Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):2666. doi:10.3390/ijms20112666
Morris, DJ. Adverse effects and drug interactions of clinical importance with antiviral. Drug-Safety. 1994;10(4):281-291. doi:10.2165/00002018-199410040-00002
Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirusinfection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420-1426. doi:10.1093/cid/ciy696
Ozturk NB, Muhammad H, Gurakar M, Aslan A, Gurakar A, Dao D. Liver transplantation in developing countries. Hepatol Forum. 2022;3(3):103-107. doi:10.14744/hf.2022.2022.0014
Akoh JA. Renal transplantation in developing countries. Saudi J Kidney Dis Transpl. 2011;22(4):637-650. https://www.sjkdt.org/text.asp?2011/22/4/637/82639
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
World Health Organization. Global Index Medicus. World Health Organization. [Online] 2021. [Cited: 2021.] https://www.globalindexmedicus.net/
Johanna Briggs Institute. Critical Appraisal Tools. [Online] [Cited: May 03, 2022.] http://joannabriggs.org/research/critical-appraisal-tools.html
Bruminhent J, Rotjanapan P, Watcharananan SP. Epidemiology and outcome of ganciclovir-resistant cytomegalovirus infection after solid organ transplantation: a single transplant center experience in Thailand. Transplant Proc. 2017;49(5):1048-1052. doi:10.1016/j.transproceed.2017.03.053
Han SH, Yoo SG, Do Han K, La Y, Lee KH. The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data. Int J Med Sci. 2021;18(14):3333-3341. doi:10.7150/ijms.62621
Julian Nunez MA, Miranda Novales MG, Flores Ruiz EM, Guerra Gallo I, Solorzano Santos F, Vazquez Rosales JG. Frecuencia de infección y enfermedad por citomegalovirus y factores de riesgo para su desarrollo en pacientes pediátricos. Bol méd Hosp Infant Méx. 2012;69(5):355-66.
De Matos SB, Meyer R de Mendonça Lima FW. Cytomegalovirus infection after renal transplantation: occurrence, clinical features, and the cut off for Antigenemia in a University Hospital in Brazil. Infect Chemother. 2017;49(4):255-261. doi:10.3947/ic.2017.49.4.255
Carvalho FR, Cosendey RIJ, Souza CF, et al. Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy. Braz J Infect Dis. 2017;21(1):51-56. doi:10.1016/j.bjid.2016.09.016
Davila FA, Pareja MJ, Rodriguez ES, Fajardo WR, Luna RD, Florez KV. Survival analysis after kidney transplant (retrospective cohort). Urologia Colombiana. 2017;26(1):12-16. doi:10.1016/j.uroco.2016.03.005
Rao A, Konnur A, Gang S, Hegde U, Soni S, Jojera A. Surveillance of viral infections in renal transplant recipients-a prospective observational study. Ind J Transpl. 2020;14(2):116-214. doi:10.4103/ijot.ijot_73_19
Lee YM Kim YH, Han DJ, et al. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients. Transpl Infect Dis. 2014;16(3):397-402. doi:10.1111/tid.12227
Zhilkin I, Tsirulnikova O, Monakhov A, et al. cytomegalovirus infection after transplantation in pediatric liver recipients. Transplantation. 2018;102:S358. doi:10.1097/01.tp.0000543103.15192.de
Costa FA, Soki MN, Andrade PD, et al. Simultaneous monitoring of CMV and human herpesvirus 6 infections and diseases in liver transplant patients: one-year follow-up. Clinics. 2011;66(6):949-953. doi:10.1590/S1807-59322011000600005
Kou J, Zhu J, Fan H, et al. Clinical predictors of cytomegalovirus infection after liver transplantation. Zhonghua wai ke za zhi [Chin J Surg]. 2015;53(4):270-273.
Yadav SK, Saigal S, Choudhary NS, et al. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: a single center experience. Transpl Infect Dis. 2018;20(4):e12905. doi:10.1111/tid.12905
Contreras K, Brochero MJV, Manrique J, Garcia PK, Rodriguez P, Gonzalez CA. Incidencia y características clínicas de pacientes trasplantados renales con infección y enfermedad por citomegalovirus en un centro de trasplante. Acta méd colomb. 2018;43(1): 20-23. doi:10.36104/amc.2018.957
Ko EJ, Yu JH, Yang CW Chung BH. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy. Korean J Intern Med. 2019;34(2):375-382. doi:10.3904/kjim.2017.040
Kang R, Han, S, Kim JM, et al. Postoperative hyperglycemia may negatively impact cytomegalovirus infection in seropositive liver transplant recipients: a retrospective cohort study. Transpl Int. 2020;33(1):68-75. doi:10.1111/tri.13496
Pinto CH, Tedesco-Silva Jr H, Felipe CR, et al. Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation. Braz J Infect Dis. 2016;20(6):576-84. doi:10.1016/j.bjid.2016.08.007
Felipe CR, Ferreira AN, Bessa A, et al. The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. J Bras Nefrol. 2017;39:413-423. doi:10.5935/0101-2800.20170074
Moura LRR, Tonato EJ, Ferraz EA, et al. Immunological induction with thymoglobulin: reduction in the number of doses in renal transplant from deceased donor. Einstein (Sao Paulo). 2011;9:56-65. doi:10.1590/S1679-45082011AO1838
Kim T, Lee YM, Lee SO, et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med. 2016;31(5):961-970. doi:10.3904/kjim.2015.079
de Paula MI, Bowring MG, Shaffer AA, et al. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis-a cohort single-center study. Transpl Int. 2021;34(2):339-352. doi:10.1111/tri.13800
Ono G, Medina Pestana JO, Aranha Camargo LF. Late cytomegalovirus (CMV) infections after kidney transplantation under the preemptive strategy: risk factors and clinical aspects. Transpl Infect Dis. 2019;21(2):e13035. doi:10.1111/tid.13035
Foresto RD, Hazin MA, Zapata A, Santos DWC. Safety and efficacy of management of refractory cytomegalovirus infection in kidney transplant recipients treated with foscarnet and conversion from antimetabolite to mtor inhibitor. J Am Soc Nephrol. 2018.29:658
Chiasakul T, Townamchai N, Jutivorakool K et al. Risk factors of cytomegalovirus disease in kidney transplant recipients: a single-center study in Thailand. Transplant Proc. 2015;47(8):2460-2464. doi:10.1016/j.transproceed.2015.08.011
Brasil IRC, Custodio-Lima J, Sampaio RL, et al. Pre-emptive therapy for cytomegalovirus in post-transplantation liver patients with donor-positive/recipient-negative serostatus. Transplant Proc. 2017;49(4):871-3. doi:10.1016/j.transproceed.2017.03.003
Diaz JS, Jaimes FA. Cytomegalovirus disease, short-term cardiovascular events and graft survival in a cohort of kidney transplant recipients with high CMV IgG seroprevalence. Progr Transpl. 2021;31(2):126-132. doi:10.1177/152692482110027
Diaz J, Henao J, Rodelo J, Garcia A, Arbelaez M, Jaimes F. Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients. Transplant Proc. 2014;46(1):160-166. doi:10.1016/j.transproceed.2013.07.070
Rajendiran AK, Jeyachandran D, Gopalakrishnan N, Arumugam V, Thanigachalam D Ramanathan S. Cytomegalovirus infection and kidney transplantation-a retrospective study of risk factors and long-term clinical outcome. Ind J Transpl. 2021;15(2):125-130. doi:10.4103/ijot.ijot_116_20
Kim SJ, Rhu J, Yoo H, et al. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation. Journal of Clinical Medicine. 2020;9(5):1320. doi:10.3390/jcm9051320
Watcharananan SP, Louhapanswat S, Chantratita W, Jirasiritham S, Sumethkul V. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome. Transplant Proc. 2012;44(3):701-705. doi:10.1016/j.transproceed.2011.12.029
Kır O, Zeytinoğlu A, Arda B, Yılmaz M, Aşçı G, Töz H. Impact of prophylaxis vs pre-emptive approach for cytomegalovirus infection in kidney transplant recipients. Transplant Proc. 2017;49(3):537-540. doi:10.1016/j.transproceed.2017.01.027
Arroyo-Orvañanos J, Hernandez-Plata JA, Erro-Aboytia R, Nieto-Zermeno J, Reyes-Lopez A, Varela-Fascinetto G. Cytomegalovirus infection and disease in pediatric liver transplantation: burden of disease under a preemptive therapy approach. Pediatr Transplant. 2022;27:e14356. doi:10.1111/petr.14356
Gao P, Gao J, Li Z, et al. Effectiveness of oral ganciclovir on prevention of cytomegalovirus infection after liver transplantation. Chin J Organ Transpl. 2015;36(1):27-29.
Kim SI, Kim CJ, Kim YJ, et al. Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching. Transplant Proc. 2012;44(3):787-790. doi:10.1016/j.transproceed.2012.01.073
Kirisri S, Vongsakulyanon A, Kantachuvesiri S, Razonable RR, Bruminhent J. Predictors of CMV infection in CMV-seropositive kidney transplant recipients: impact of pretransplant CMV-specific humoral immunity. Open Forum Infect Dis. 2021;8(6):ofab199. doi:10.1093/ofid/ofab199
Chitasombat MN, Watcharananan SP. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: a retrospective cohort study. F1000Research. 2018;7:1568. doi:10.12688/f1000research.16321.1
Bal Z, Uyar ME, Tutal E, et al. Cytomegalovirus infection in renal transplant recipients: one center's experience. Transplant Proc. 2013;45(10):3520-3523. doi:10.1016/j.transproceed.2013.08.098
Yun JH, Lee SO, Jo KW, et al. Infections after lung transplantation: time of occurrence, sites, and microbiologic etiologies. Korean J Intern Med. 2015;30(4):506-514. doi:10.3904/kjim.2015.30.4.506
Wadhawan M, Gupta S, Goyal N, et al. Cytomegalovirus infection: Its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Liver Transpl. 2012;18:1448-1455. doi:10.1002/lt.23540
Kwak SH, Lee SH, Park MS, et al. Risk factors for cytomegalovirus reactivation in lung transplant recipients. Lung. 2020;198(5):829-838. doi:10.1007/s00408-020-00380-z
Bruminhent J, Bushyakanist A, Kantachuvesiri S, Kiertiburanakul S. A nationwide survey of cytomegalovirus prevention strategies in kidney transplant recipients in a resource-limited setting. Open Forum Infect Dis. 2019;6(9):ofz322. doi:10.1093/ofid/ofz322
Feng S, Yang J, Wang W, et al. Incidence and risk factors for cytomegalovirus infection in patients with kidney transplantation: a single-center experience. Transplant Proc. 2016;48(8):2695-9. doi:10.1016/j.transproceed.2016.08.015
Santos SDRD, Bafi AT, Freitas FGRD, Azevedo LCPD, Machado FR. Prevalência de doença por citomegalovírus em transplantados renais em unidade de terapia intensiva. Rev Bras Ter Intensiva. 2017;29:436-443. doi:10.5935/0103-507X.20170070
Li Y, Yan H, Xue WJ, et al. Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China. Ann Transplant. 2013;18(1):124-134. doi:10.12659/AOT.883859
Natori Y, Humar A, Husain S, et al. Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation. 2017;101(6):1449-1454. doi:10.1097/TP.0000000000001338
Reischig T, Kacer M, Hruba P, et al. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation. Antiviral Therapy. 2017;22(6):203-213. doi:10.3851/IMP3129
Paulsen G, Cumagun P, Mixon E, Fowler K, Feig D, Shimamura M. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis. Pediatr Transpl. 2019;23(3):e13382. doi:10.1111/petr.13382
Mehta K, Al-Yabes O, Allen A, et al. Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: a hospital-based analysis. Pediatric Transplantation. 2020;24(1):e13650. doi:10.1111/petr.13650
Chaiyapak T, Borges K, illiams A, et al. Incidence of cytomegalovirus DNAemia in pediatric kidney transplant recipients after cessation of antiviral prophylaxis. Transplantation. 2018;102(8):1391-1396. doi:10.1097/TP.0000000000002115
Singh T, Peery S, Astor BC, Parajuli S, Djamali A, Panzer SE. Cause of end-stage renal disease is not a risk factor for cytomegalovirus infection after kidney transplant. Transplant Proc. 2019;51(6):1810-1815. doi:10.1016/j.transproceed.2019.02.029
Toyoda M, Shin BH, Ge S, et al. Impact of desensitization on antiviral immunity in hla-sensitized kidney transplant recipients. J Immunol Res. 2017;2017:5672523. doi:10.1155/2017/5672523
Hemmersbach-Miller M, Alexander BD, Pieper CF, Schmader KE. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. Eur J Clin Microbiol Infect Dis. 2020;39(3):455-463. doi:10.1007/s10096-019-03744-3
Khan S, Fischman C, Huprikar S. Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience. Transpl Infect Dis. 2017;19(6):e12780. doi:10.1111/tid.12780
Heliovaara E, Husain S, Martinu T, et al. Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes. J Heart Lung Transplant. 2019;38(12):1268-1274. doi:10.1016/j.healun.2019.09.005
Kabbani D, Hirji I, Hernandez C, et al. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis. Transpl Infect Dis. 2019;21(4)e13094. doi:10.1111/tid.13094
Herrera S, Khan B, Singer LG, et al. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: a retrospective study. Transpl Infect Dis. 2020;22(4):e13277. doi:10.1111/tid.13277
Das BB, Prusty BK, Niu J & Sue PK. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. Pediatr Transpl. 2020;24:e13750. doi:10.1111/petr.13750
Avery RK, Silveira FP, Benedict K, et al. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. Transpl Infect Dis. 2018;20(3):e12877. doi:10.1111/tid.12877
Tague LK, Scozzi D, Wallendorf M, et al. Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. Am J Transplant. 2020;20:250-261. doi:10.1111/ajt.15581
Jewani PK, Pouch SM, Kissling KT. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin. Clinical Transplantation. 2018;32(11):e13420. doi:10.1111/ctr.13420
Mabilangan C, Preiksaitis JK, Cervera C, et al. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Transpl Infect Dis. 2019;21(1):e13015. doi:10.1111/tid.13015
Reekie, J, et al. The risk of CMV infection and recurrence among SOT recipients - Poster 1079. IDWeek2020. 2020.
Khurana MP, Lodding IP, Mocroft A, et al. Risk factors for failure of primary (val) ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients. Open Forum Infect Dis. 2019;6(6):ofz215. doi:10.1093/ofid/ofz215
Serrano-Alonso M, Guillen-Grima F, Martin-Moreno P, et al. Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation. Transpl Infect Dis. 2018;20(3):e12873. doi:10.1111/tid.12873
Molina-Ortega A, Martín-Gandul C, Mena-Romo JD, et al. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect. 2019;25(6):753-758. doi:10.1016/j.cmi.2018.09.019
Verma A, Palaniswamy K, Cremonini G, Heaton N, Dhawan A. Late cytomegalovirus infection in children: High incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients. Pediatr Transpl. 2017;21(3). doi:10.1111/petr.12879
Nicastro E, Giovannozzi S, Stroppa P, et al. Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. Transplantation. 2017;101(4):804-810. doi:10.1097/TP.0000000000001531
Singh R, Peters-Sengers H, Remmerswaal EB, et al. Clinical consequences of primary CMV infection after renal transplantation: a case-control study. Transpl Int. 2020;33(9):1116-1127. doi:10.1111/tri.13667
Schachtner T, Zaks M, Otto NM, Kahl A Reinke P. Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications. Transpl Infect Dis. 2017;19(5):e12742. doi:10.1111/tid.12742
Komorowska-Jagielska K, Heleniak Z, Debska-Slizien A. Cytomegalovirus status of kidney transplant recipients and cardiovascular risk. Transplant Proc. 2018;50(6):1868-1873. doi:10.1016/j.transproceed.2018.03.126
López-Oliva MO, Flores J, Madero R, et al. Cytomegalovirus infection after kidney transplantation and long-term graft loss. Nefrologia. 2017;37(5):515-525. doi:10.1016/j.nefroe.2016.11.018
Strakosha A, Pasko N, Cadri V. Cytomegalovirus infection in renal transplant recipient. Transpl Int. 2017;30(2):494-495. https://dx.doi.org/10.1111/tri.13053
Bischof N, Wehmeier C, Dickenmann M, et al. Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation. Nephrol Dial Transpl. 2020;35(2):346-356. doi:10.1093/ndt/gfz268
Cunha L, Laranjinha I, Birne R, et al. Late cytomegalovirus infection in kidney transplant recipients after a six-month prevention protocol. Int J Organ Transplant Med. 2019;10(1):1-12.
Lollinga WT, Rurenga-Gard L, van Doesum W, et al. High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function-a retrospective study. Transpl Int. 2017;30:817-826. doi:10.1111/tri.12972
Hakimi Z, Aballéa S, Ferchichi S, et al. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis. 2017;19(5):203-213. doi:10.1111/tid.12732
Jaamei N, Koutsokera A, Pasquier J, et al. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients. Transpl Infect Dis. 2018;20(4):e12732. doi:10.1111/tid.12893
Monforte V, Sintes H, López-Gallo C, et al. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. Transpl Infect Dis. 2017;19(3). doi:10.1111/tid.12694
Eriksson M, Jokinen JJ, Söderlund S, Hämmäinen P, Lommi J, Lemström K. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin. Transpl Infect Dis. 2018;20(3):e12868. doi:10.1111/tid.12868
Aryal S, Katugaha SB, Cochrane A, et al. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transpl Infect Dis. 2019;21(6):e13166. doi:10.1111/tid.13166
Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191
Caliendo A. Overview of diagnostic tests for cytomegalovirus infection. UpToDate. [Online] 2020. [Cited: Jul 06, 2022.] https://www.medilib.ir/uptodate/show/8291#top
Reekie J, Khurana MP, Lodding IP, et al. 1079. The risk of CMV infection and recurrence among SOT recipients. Open Forum Infect Dis. 2020;7(Suppl 1):S567-S568.
Kniepeiss D, Fuehrlinger K, Schrem H, et al. Infection safety of low-dose ATG induction in liver transplantation. Transpl Int. 2019;32(S4):S6-S27.
Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis. 2008;46(5):732-740. doi:10.1086/527397
Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011;43:2145-2148. doi:10.1016/j.transproceed.2011.05.007
Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82:S15-S17. doi:10.1097/01.tp.0000230460.42558.b0
Chuleerarux N, Thongkam A, Manothummetha K, et al. Does post-transplant cytomegalovirus increase the risk of invasive aspergillosis in solid organ transplant recipients? A systematic review and meta-analysis. Journal of Fungi. 2021;7(5):327. doi:10.3390/jof7050327
Bergamasco A, Goyer C, Arredondo-Bisono T, et al. epidemiology of resistant and refractory cytomegalovirus infection following solid organ or haematopoietic stem cell transplant: a systematic review. Bone Marrow Transplant. 2021;56(1):263-264. doi:10.1038/s41409-021-01343-5
Limaye AP, Budde K, Humar A, et al. LB2307. Safety and efficacy of letermovir versus valganciclovir for prevention of cytomegalovirus disease in CMV High-risk D+/R- kidney transplant recipients : A phase 3 randomised study. Open Forum Infect Dis. 2022;9(Suppl 2):ofac492.1897.
Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690-701. doi:10.1093/cid/ciab988